5 Key Takeaways

• 1

  The HHS announced a department-wide initiative to enhance clinical research and accelerate new treatment development.

• 2

  Operation TrialBlazer outlines strategies to address global competition in clinical trials, particularly from China.

• 3

  The FDA is proposing a pilot program to shorten timelines from drug identification to Phase 1 trials by clarifying regulatory expectations.

• 4

  The roadmap includes plans for a single IRB model for multisite studies to streamline trial startup and enrollment.

• 5

  NIH is increasing support for clinical trials and promoting the use of AI and real-world data to enhance therapy development.